Datopotamab and Dato-DXd, but not CTL-ADC, were highly effective in inducing ADCC against primary endometrial cancer cell lines expressing TROP2 at high levels [i.e., END(K)254 and END(K)265; Fig. 4B and C]. The gene discussed is TACSTD2; the disease is endometrial cancer.